Sun Hyun Bae1, Mi-Sook Kim2, Won Il Jang3, Chul-Seung Kay4, Woochul Kim5, Eun Seog Kim6, Jin Ho Kim7, Jin Hee Kim8, Kwang Mo Yang9, Kyu Chan Lee10, A Ram Chang11, Sunmi Jo12. 1. Department of Radiation Oncology, Soonchunhyang University College of Medicine, Bucheon. 2. Korea Institute of Radiological & Medical Sciences, Seoul mskim@kcch.re.kr. 3. Korea Institute of Radiological & Medical Sciences, Seoul. 4. Incheon St Mary's Hospital, The Catholic University of Korea, Inchon. 5. Inha University Hospital, Inha University School of Medicine, Incheon. 6. Soonchunhyang University College of Medicine, Cheonan. 7. Seoul National University, College of Medicine, Seoul. 8. Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu. 9. Dongnam Institute of Radiological & Medical Sciences, Busan. 10. Gachon University Gil Medical Center, Gachon University of Medicine and Science, Incheon. 11. Soonchunhyang University College of Medicine, Seoul. 12. Haeundae Paik Hospital, Inje University School of Medicine, Busan, Republic of Korea.
Abstract
OBJECTIVE: To investigate practical patterns for stereotactic body radiotherapy to hepatocellular carcinoma in Korea. METHODS: In June 2013, the Korean Stereotactic Radiosurgery Group of the Korean Society for Radiation Oncology conducted a national patterns-of-care survey about stereotactic body radiotherapy to the liver lesion in hepatocellular carcinoma, consisting of 19 questions and 2 clinical scenarios. RESULTS: All 208 radiation oncologists (100%), who are regular members of Korean Society for Radiation Oncology, responded to this survey. Among these, 95 radiation oncologists were specialists for hepatology; 64 physicians did not use stereotactic body radiotherapy for hepatocellular carcinoma, and 31 physicians used stereotactic body radiotherapy. Most physicians (52%) performed stereotactic body radiotherapy to hepatocellular carcinoma in ≤5 cases per year. Physicians applied stereotactic body radiotherapy according to tumour size and baseline Child-Pugh class. All physicians agreed the use of stereotactic body radiotherapy to 2.8-cm hepatocellular carcinoma with Child-Pugh class of A, while 23 physicians (74%) selected stereotactic body radiotherapy for Child-Pugh class of B. Nineteen physicians (61%) selected stereotactic body radiotherapy to 5-cm hepatocellular carcinoma with Child-Pugh class of A, and only 14 physicians (45%) selected stereotactic body radiotherapy for Child-Pugh class of B. On the other hand, the preferred dose scheme was same as 60 Gy in three fractions. CONCLUSIONS: Among radiation oncologists in Korea, there was diversity in the practice for stereotactic body radiotherapy to the liver lesion in hepatocellular carcinoma. Additional prospective studies are necessary to standardize the practice and establish Korea-specific practice guidelines for hepatocellular carcinoma stereotactic body radiotherapy.
OBJECTIVE: To investigate practical patterns for stereotactic body radiotherapy to hepatocellular carcinoma in Korea. METHODS: In June 2013, the Korean Stereotactic Radiosurgery Group of the Korean Society for Radiation Oncology conducted a national patterns-of-care survey about stereotactic body radiotherapy to the liver lesion in hepatocellular carcinoma, consisting of 19 questions and 2 clinical scenarios. RESULTS: All 208 radiation oncologists (100%), who are regular members of Korean Society for Radiation Oncology, responded to this survey. Among these, 95 radiation oncologists were specialists for hepatology; 64 physicians did not use stereotactic body radiotherapy for hepatocellular carcinoma, and 31 physicians used stereotactic body radiotherapy. Most physicians (52%) performed stereotactic body radiotherapy to hepatocellular carcinoma in ≤5 cases per year. Physicians applied stereotactic body radiotherapy according to tumour size and baseline Child-Pugh class. All physicians agreed the use of stereotactic body radiotherapy to 2.8-cm hepatocellular carcinoma with Child-Pugh class of A, while 23 physicians (74%) selected stereotactic body radiotherapy for Child-Pugh class of B. Nineteen physicians (61%) selected stereotactic body radiotherapy to 5-cm hepatocellular carcinoma with Child-Pugh class of A, and only 14 physicians (45%) selected stereotactic body radiotherapy for Child-Pugh class of B. On the other hand, the preferred dose scheme was same as 60 Gy in three fractions. CONCLUSIONS: Among radiation oncologists in Korea, there was diversity in the practice for stereotactic body radiotherapy to the liver lesion in hepatocellular carcinoma. Additional prospective studies are necessary to standardize the practice and establish Korea-specific practice guidelines for hepatocellular carcinoma stereotactic body radiotherapy.
Authors: A Sahgal; D Roberge; D Schellenberg; T G Purdie; A Swaminath; J Pantarotto; E Filion; Z Gabos; J Butler; D Letourneau; G L Masucci; L Mulroy; A Bezjak; L A Dawson; M Parliament Journal: Clin Oncol (R Coll Radiol) Date: 2012-05-24 Impact factor: 4.126
Authors: Louis Potters; Michael Steinberg; Christopher Rose; Robert Timmerman; Samuel Ryu; James M Hevezi; James Welsh; Minesh Mehta; David A Larson; Nora A Janjan Journal: Int J Radiat Oncol Biol Phys Date: 2004-11-15 Impact factor: 7.038
Authors: Alejandra Méndez Romero; Wouter Wunderink; Shahid M Hussain; Jacco A De Pooter; Ben J M Heijmen; Peter C J M Nowak; Joost J Nuyttens; Rene P Brandwijk; Cees Verhoef; Jan N M Ijzermans; Peter C Levendag Journal: Acta Oncol Date: 2006 Impact factor: 4.089
Authors: Sun Hyun Bae; Mi-Sook Kim; Won Il Jang; Chul-Seung Kay; Woochul Kim; Eun Seog Kim; Jin Ho Kim; Jin Hee Kim; Kwang Mo Yang; Kyu Chan Lee; A Ram Chang; Sunmi Jo Journal: Cancer Res Treat Date: 2014-11-24 Impact factor: 4.679
Authors: Won Il Jang; Mi-Sook Kim; Sun Hyun Bae; Chul Koo Cho; Hyung Jun Yoo; Young Seok Seo; Jin-Kyu Kang; So Young Kim; Dong Han Lee; Chul Ju Han; Jin Kim; Su Cheol Park; Sang Bum Kim; Eung-Ho Cho; Young Han Kim Journal: Radiat Oncol Date: 2013-10-27 Impact factor: 3.481
Authors: Sun Hyun Bae; Hee Chul Park; Won Sup Yoon; Sang Min Yoon; In-Hye Jung; Ik Jae Lee; Jun Won Kim; Jinsil Seong; Tae Hyun Kim; Taek-Keun Nam; Youngmin Choi; Sun Young Lee; Hong Seok Jang; Dong Soo Lee; Jin Hee Kim Journal: Cancer Res Treat Date: 2019-04-10 Impact factor: 4.679
Authors: Jared R Robbins; Ryan K Schmid; Abdulrahman Y Hammad; Thomas Clark Gamblin; Beth A Erickson Journal: Cancer Med Date: 2019-01-31 Impact factor: 4.452